Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. In this study, we investigated efficacy and safety at 104 weeks after randomization. RESEARCH DESIGN AND METHODS: DURATION-8 was a 104-week, multicenter, double-blind, randomized, active-controlled, phase 3 trial. In total, 695 adults (aged ≥18 years) with type 2 diabetes and inadequate glycemic control (HbA1c 8.0–12.0% [64–108 mmol/mol]) despite stable metformin monotherapy (≥1,500 mg/day) were randomly assigned (1:1:1) to receive exenatide 2 mg QW plus once-daily dapagliflozin 10 mg, exenatide QW plus placebo, or dapagliflozin plus placebo. All 104-week evaluations were exploratory. RESULTS: At week 104, 431 (62.0%) patients completed treatment. The adjusted least squares mean change (SE) from baseline to week 104 in HbA1c was greater with exenatide QW plus dapagliflozin (−1.70% [0.11]) versus exenatide QW plus placebo (−1.29% [0.12]; P = 0.007) and dapagliflozin plus placebo (−1.06% [0.12]; P < 0.001). Clinically relevant changes in FPG, 2-h PPG, weight, and SBP were also observed with exenatide QW plus dapagliflozin. There were no unexpected safety findings, and exenatide QW plus dapagliflozin was well tolerated, with no episodes of major hypoglycemia. CONCLUSIONS: In this exploratory analysis, among those individuals who completed the trial without rescue therapy, there was clinically relevant efficacy over 2 years with exenatide QW plus dapagliflozin, with no unexpected safety findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a randomized, controlled trial of patients with type 2 diabetes and inadequate glycemic control while on stable metformin monotherapy, compared to dapagliflozin alone, exenatide plus dapagliflozin produced clinically relevant changes in body weight, fasting plasma glucose, 2-h post-prandial glucose, and systolic blood pressure [115].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [115]
In the citing paper
“In a randomized, controlled trial of patients with type 2 diabetes and inadequate glycemic control while on stable metformin monotherapy, compared to dapagliflozin alone, exenatide plus dapagliflozin produced clinically relevant changes in body weight, fasting plasma glucose, 2-h post-prandial glucose, and systolic blood pressure [115].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [115]
In the citing paper
“In a randomized, controlled trial of patients with type 2 diabetes and inadequate glycemic control while on stable metformin monotherapy, compared to dapagliflozin alone, exenatide plus dapagliflozin produced clinically relevant changes in body weight, fasting plasma glucose, 2-h post-prandial glucose, and systolic blood pressure [115].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [115]
In the citing paper
“In a randomized, controlled trial of patients with type 2 diabetes and inadequate glycemic control while on stable metformin monotherapy, compared to dapagliflozin alone, exenatide plus dapagliflozin produced clinically relevant changes in body weight, fasting plasma glucose, 2-h post-prandial glucose, and systolic blood pressure [115].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 398
Self-citationZinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376
Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30023-8 · Cited by 266
Self-citationDel Prato, S., Nauck, M., Durán‐Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., & Parikh, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12459 · Cited by 233
Jabbour, S., Seufert, J., Scheen, A., Bailey, C. J., Karup, C., & Langkilde, A. M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13124 · Cited by 157
Self-citationJabbour, S. A., Frías, J. P., Hardy, E., Ahmed, A., Wang, H., Öhman, P., & Guja, C. (2018) · Diabetes Care · doi:10.2337/dc18-0680 · Cited by 97
Self-citation
Cited by
Gourdy, P., Darmon, P., Dievart, F., Halimi, J.-M., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 127
“The only exception was DURATION-8, a 104-week, active-controlled, phase III trial, evaluating the combination of once-weekly subcutaneous exenatide plus once-daily oral dapagliflozin, simultaneously added to stable metformin monotherapy, in 695 patients with T2DM and poor glycemic control [36].”
BackgroundCombination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
“Early studies such as DURA-TION-8 in patients with T2DM, showed that combination treatment with SGLT2 inhibitors and GLP1 receptor agonists had greater beneficial effects on blood glucose levels, body weight and blood pressure in people with diabetes than either therapy alone 105 .”
Li, C., Luo, J., Jiang, M., & Wang, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838277 · Cited by 96
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Patel, R., Wadid, M., Makwana, B., Kumar, A., Khadke, S., Bhatti, A., Banker, A., Husami, Z., Labib, S., Venesy, D., et al. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2024.07.006 · Cited by 72
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 75
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 74
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 77
“It should be taken into consideration that such an increased risk for hypoglycemia may be due to the simultaneous use of SGLT2 inhibitors and GLP-1-R agonists with other hypoglycemic agents, such as insulins or sulphonylureas, by some of the patients [59,60].”
Backgroundvan Ruiten, C. C., Smits, M. M., Kok, M. D., Serné, E. H., van Raalte, D. H., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01492-x · Cited by 55
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 76
“…alone, with a mean reduction of 2.0% vs. 1.6%, and 1.4%, respectively In addition, a combination approach was behind the biggest weight loss, which more than doubled that seen with either agent alone versus 1.54% and 2.22% for exenatide or dapagliflozin monotherapy, respectively [150].”
InfluentialManagement of type 2 diabetes in chronic kidney disease
Triozzi, J. L., Gregg, L. P., Virani, S. S., & Navaneethan, S. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002300 · Cited by 51
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Li, C. X., Liu, L. Y., Zhang, C. X., Geng, X. H., Gu, S. M., Wang, Y. Q., Liu, H., Xie, Q., & Liang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1238399 · Cited by 46
“The median duration of the intervention was 24 weeks (12-338).”
BackgroundMousavi, A., Shojaei, S., Soleimani, H., Semirani-Nezhad, D., Ebrahimi, P., Zafari, A., Ebrahimi, R., Roozbehi, K., Harrison, A., Syed, M., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01635-6 · Cited by 44
“Jabbour et al. [36, 37] reported UTI as the most common adverse event in their trial.”
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Huang, W., Chen, Y., Li, Z., He, F., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810882 · Cited by 36
“A other 104-week trial came to the similar con lusi n that the combination of exenatide and d pagliflozin was beneficial for glycemic control in patients with T2DM and had favorable safety [130].”
BackgroundSGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Shi, N., Shi, Y., Xu, J., Si, Y.-X., Yang, T., Zhang, M., Ng, D. M., Li, X., & Xie, F. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.668368 · Cited by 39
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
Lunati, M. E., Cimino, V., Bernasconi, D. P., Gandolfi, A., Morpurgo, P. S., Tinari, C., Lazzaroni, E., Baruffaldi, L., Muratori, M., Montefusco, L. B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107040 · Cited by 36
der Beek, A. B. V. D. A., Apperloo, E. M., Jongs, N., Rouw, D. B., Sjöström, C. D., Friedli, I., Johansson, L., van Raalte, D. H., Hoogenberg, K., & Heerspink, H. J. L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15033 · Cited by 32
Self-citationRroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
“Multiple studies, including randomized controlled trials [306–308], non-randomized investigations [297–300], real-world analyses [309,310], and post hoc evaluations of cardiovascular outcomes trials [311–315], further support their benefits in glycemic control, weight reduction, and blood pressure…”
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
Mallik, R., & Chowdhury, T. A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221081601 · Cited by 31
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
“Dapagliflozin 10 mg: Dapagliflozin alone caused a 2.7 kg Weight loss after 52 weeks, while combined with exenatide, loss increased to 3.8 kg [41].”
Influential2023 update on Italian guidelines for the treatment of type 2 diabetes
Mannucci, E., Candido, R., Monache, L. D., Gallo, M., Giaccari, A., Masini, M. L., Mazzone, A., Medea, G., Pintaudi, B., Targher, G., et al. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02107-x · Cited by 31
Colombijn, J. M. T., de Leijer, J. F., Visseren, F. L. J., Verhaar, M. C., van Raalte, D. H., Sattar, N. A., Vernooij, R. W. M., & van Sloten, T. T. (2025) · Diabetologia · doi:10.1007/s00125-025-06565-6 · Cited by 37
“We did not include RCTs in this meta-analysis because to date only one RCT [22] has compared combination therapy with an SGLT2 inhibitor and a GLP-1 RA vs SGLT2 inhibitor or GLP-1 RA monotherapy.”
Zheng, Z., He, D., Chen, J., Xie, X., Lu, Y., Wu, B., & Jiang, X. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01256-9 · Cited by 33
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 26
Yepes, C. A., Cardenas-Moreno, I. C., Daza-Arnedo, R., Fériz, K., Yama-Mosquera, E., Rincón, A. R., Castillo, G. A., Suarez-Rodriguez, A. F., Carreño-Jiménez, J., & Builes-Montaño, C. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01722-x · Cited by 27
Yoosuf, B. T., Muhammed Favas, K. T., Spoorthy, D. P., Saini, A., Garg, P., Medenica, S., Dutta, P. R., & Bansal, D. (2025) · Endocrine · doi:10.1007/s12020-025-04393-7 · Cited by 24
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“The DURATION-8 trial (NCT02229396) demonstrated that combining SLGT2is with GLP1-RAs in T2D resulted in greater improvements in glucose, BP and body weight compared with either therapy alone [66 ].”
Tuersun, A., Hou, G., & Cheng, G. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.07.011 · Cited by 20
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 18
“…( exenatide once weekly) used in combination with a SGLT2 inhibitor ( dapagliflozin) is safe and that the combination resulted in superior glycemia lowering, and clinically relevant weight and blood pressure reduction, compared with either agent used alone over two years of treatment [124 ].”
Backgroundvan Ruiten, C. C., Veltman, D. J., Nieuwdorp, M., & IJzerman, R. G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.863592 · Cited by 16
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Cersósimo, E., Alatrach, M., Solis‐Herrera, C., Baskoy, G., Adams, J. M., HANSIS-DIARTE, A. A., Gastaldelli, A., Chávez, A. O., Triplitt, C. L., & DeFronzo, R. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad438 · Cited by 14
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Lee, C., Lui, D. T. W., Mak, L., Fong, C. H.-Y., Chan, K. S., Mak, J. H., Cheung, C. Y. Y., Chow, W., Woo, Y. C., Yuen, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16049 · Cited by 12
Homoródi, N., Varga, É., Szabó, Z., Sztanek, F., & Harangi, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112595 · Cited by 15
“The study proved that exenatide plus dapagliflozin provided sustained improvements in glycemia, weight, and systolic blood pressure over 52 weeks as well as over 2 years, with no unexpected safety findings [115–117].”
Is polypharmacy the future for pharmacological management of obesity?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100322 · Cited by 12
Tian, C., Yang, Z. R., Zhao, S., Zhang, P., & Li, R. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.09.028 · Cited by 11
Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis
Li, P., Chen, W., Chen, R., Zhang, H., Yu, Z., Yan, H., Du, B., & Yang, P. C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1558367 · Cited by 8
Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review
Zhang, H., Chen, J., Wang, N., Chen, W., Xu, Y., & Gui, D. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70077 · Cited by 8
“The DURATION‐8 Study demonstrated that from baseline to week 104 in HbA1c was greater with exenatide (a GLP‐1 receptor agonist) QW plus dapagliflozin (an SGLT2i) versus mono-therapy [86].”
López‐Cano, C., Santos, M. D., Sánchez, E., Martí, R., Bueno, M., Gutiérrez-Carrasquilla, L., & Lecube, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-07250-z · Cited by 10
Gudoor, R., Suits, A., & Shubrook, J. H. (2023) · Diabetology · doi:10.3390/diabetology4030032 · Cited by 8
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
“Severe hypoglycaemia was not observed in any of the treatment arms [188].”
Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Avogaro, A., Neccia, M., Delfini, M., Franculli, A., Enea, G., Magli, A., Bemporad, J. A., & Fadini, G. P. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02666-9 · Cited by 4
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Thewjitcharoen, Y., Yenseung, N., Butadej, S., Nakasatien, S., Chotwanvirat, P., Chatchomchuan, W., Wanothayaroj, E., Krittiyawong, S., & Himathongkam, T. (2023) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.038.01.11 · Cited by 5
Xu, B., Kang, B., Li, S., Chen, J., & Zhou, J. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-01924-0 · Cited by 7
Samuel, A. H., Kshatri, A. H. S., Babu, R. N., Patel, H. S., Viswanathan, S. H., Challa, M. S. R., & Swathi, N. L. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102494 · Cited by 4
Kalathiya, U. N., Herrin, J. S., SWARNA, K. S., Deng, Y., Polley, E. C., Neumiller, J. J., Galindo, R. J., Umpierrez, G. E., Ross, J. S., Mickelson, M. M., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.004 · Cited by 5
Tantawy, D., Rabih, M. R. M., Mohamed, R. S., Ali, M. K., Aldeen, R. S. A. M. S., Abdelkarim, A. O. A., & Mohamedzain, T. G. A. (2025) · Cureus · doi:10.7759/cureus.96218 · Cited by 4
“The interventions examined were combinations of SGLT2i and GLP-1 RAs, including dapagliflozin with exenatide [14], liraglutide added to SGLT2i [17], and empagliflozin with semaglutide [18-20].”
InfluentialLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Porterfield, L. R., Nadeem, S., Swanson, D., Hayek, S. S., & Vaughan, E. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01448-6 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Fisher, M., Llano, A., & McKay, G. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch5 · Cited by 1
Exenatid und Dapagliflozin auch langfristig sicher und effektiv
(2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1327-9770
Zheng, Z., He, D., Chen, J., Xie, X., Lu, Y., Wu, B., & Jiang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1850015/v1
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Che cosa non sappiamo sugli SGLT-2 inibitori
Chiriacò, M., Chatzianagnostou, K., Emdin, M., & Prato, S. D. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01510-y
Stronger Together: How GLP-1 RAs and SGLT-2 Inhibitors Revolutionize Type 2 Diabetes Treatment
Sitarek, H., Tabeau, A., Prus, J., Pięta, J., Pawlik, A., Dudek, P., Łuczak, K., Ulicka, W., Chudzikowski, M., & Prokopiuk, A. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.80.59642 · Cited by 2
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Xu, Y., Ji, G., Shi, C., Tan, Y., Wang, L., & Gui, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112954
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Figshare · doi:10.6084/m9.figshare.16696428
Zhou, L., Wu, P., Xu, Y., & Xie, B. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02697-2 · Cited by 2
Urbanovych, A. M., Sidelnyk, N. Y., & Lishchuk, O. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.3.2026.1717
Metadata
- Authors
- Jabbour, S. A., Frías, J. P., Ahmed, A., Hardy, E., Choi, J., Sjöström, C. D., & Guja, C.
- Affiliations
- Thomas Jefferson University (US)
- National Research Institute (US)
- Apex Medical Research, Chicago, IL
- AstraZeneca (United States) (US)
- Statum Research, Irvine, CA
- AstraZeneca (Sweden) (SE)
- Carol Davila University of Medicine and Pharmacy (RO)
- Corresponding author
- Jabbour, Serge A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-08-18
- Volume
- 43
- Issue
- 10
- Pages
- 2528-2536
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7510043
- OpenAlex
- W3065084537
- Cited by
- 69
- References
- 17
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 8
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, dapagliflozin, type 2 diabetes, glycemic control, HbA1c, long-term efficacy, long-term safety, weight loss, systolic blood pressure, metformin, GLP-1 receptor agonists, SGLT2 inhibitors, combination therapy, postprandial blood glucose, fasting blood glucose
- MeSH terms
- Exenatide, Adolescent, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.